Improving on nature: Redesigning ADAMTS13

Blood

Volumn 119, Issue 16, 2012, Pages 3654-3655

  Hovinga, Johanna A Kremer ^a   Voorberg, Jan ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; AUTOANTIBODY; CORTICOSTEROID; HLA DRB1 ANTIGEN; LACTATE DEHYDROGENASE; PHENYLALANINE; RECOMBINANT PROTEIN; RECOMBINANT VON WILLEBRAND FACTOR CLEAVING PROTEINASE; RITUXIMAB; TYROSINE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANTIGEN PRESENTING CELL; ARTICLE; BINDING SITE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CORTICOSTEROID THERAPY; GAIN OF FUNCTION MUTATION; GENE OVEREXPRESSION; GENETIC PREDISPOSITION; HUMAN; MEMORY CELL; MOLECULAR MIMICRY; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DOMAIN; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 84860341405     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-02-410431     Document Type: Article

References (10)

1. Jian C, Xiao J, Gong L, et al. Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Blood. 2012;119(16):3836-3843.
2. Studt JD, Kremer Hovinga JA, Radonic R, et al. Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins. Blood. 2004;103(11):4195-4197. (Pubitemid 38685362)
3. Scully M, Brown J, Patel R, McDonald V, Brown CJ, Machin S. Human leukocyte antigen association in idiopathic thrombotic thrombocytopenic purpura: evidence for an immunogenetic link. J Thromb Haemost. 2010;8(2): 257-262.
4. Pos W, Luken BM, Sorvillo N, Kremer Hovinga JA, Voorberg J. Humoral immune response to ADAMTS13 in acquired TTP. J Thromb Haemost. 2011;9(7):1285-1291.
5. Sorvillo N, Pos W, van den Berg LM, et al. The macrophage mannose receptor promotes uptake of ADAMTS13 by dendritic cells. Blood. 2012;119(16):3828-3835.
6. Pos W, Crawley JT, Fijnheer R, Voorberg J, Lane DA, Luken BM. An autoantibody epitope comprising residues R660, Y661, and Y665inthe ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF. Blood. 2010;115(8):1640-1649.
7. Pos W, Sorvillo N, Fijnheer R, et al. Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodiesinthe spacer domain. Haematologica. 2011;96(11):1670-1677.
8. Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115(8):1500-1511.
9. Plaimauer B, Kremer Hovinga JA, Juno C, et al. Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost. 2011;9(5):936-944.
10. Zheng XL, Wu HM, Shang D, et al. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica. 2010; 95(9):1555-1562.